A Study to Examine Anktiva for the Treatment of COVID-19.
← catalyst calendarSponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-04 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Long COVID
- Long COVID Syndrome
- Long Covid 19
Intervention
- Drug: Anktiva — also filed as N-803, Nogapendekin Alfa Inbakicept, NAI
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.
measured Through 30 days post final study drug administration.
Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration.
measured Through 30 days post final study drug administration.
Incidence of serious adverse events (SAEs) through 30 days post final study drug administration.
measured Through 30 days post final study drug administration.
Incidence of abnormal changes in safety laboratory tests (CBC and CMP).
measured Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as temperature in degrees Fahrenheit.
measured Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as heart rate in beats per minute.
measured Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as blood pressure in millimeters of mercury (mmHg).
measured Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as respiratory rate in breaths per minute.
measured Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as oxygen saturation in percentage.
measured Through the end of the study treatment period (approximately 75 days).
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed